

Species type and number of cases	Total	<i>N.farcinica</i>	<i>N.cyriacigeorgica</i>	<i>N.brasiliensis</i>	<i>N.otitidiscaviarum</i>	<i>N.abscessus</i> Complex ¹	<i>N.terpenica</i>	<i>N.nova</i> complex ²	<i>N.transvalensis</i> Complex ³	Other species type ⁴
Antimicrobial treatment	596	157	110	82	66	62	16	19	6	78
Sulfonamides (trimethoprim-sulfamethoxazole)	531 (89.09%)	135 (85.99%)	99 (90%)	76 (92.68%)	62 (93.94%)	54 (87.10%)	13 (81.25%)	16 (84.21%)	5 (83.33%)	71 (91.03%)
Monotherapy	161 (30.32%)	37 (27.41%)	34 (34.34%)	35 (46.05%)	12 (19.35%)	21 (38.89%)	6 (46.15%)	4 (25%)	3 (60%)	9 (12.68%)
Dual therapy with one other class of drug	215 (40.49%)	41 (30.37%)	45 (45.45%)	33 (43.42%)	26 (41.94%)	21 (38.89%)	3 (23.08%)	7 (43.75%)	1	38 (53.52%)
Combined with carbapenems (imipenem/meropenem)	68 (31.63%)	14 (34.15%)	14 (31.11%)	3	10 (38.46%)	8	1	2	0	16 (42.11%)
Combined with cephalosporins/penicillins β -lactamase inhibitors	52 (24.19%)	7	8	19 (57.58%)	5	6	1	4	0	2
Combined with amikacin	19	7	4	1	1	1	0	0	0	5
Combined with linezolid	43 (20%)	9 (21.95%)	12 (26.67%)	3	7	4	1	0	0	7
Combined with fluoroquinolones(levofloxacin/moxifloxacin/ciprofloxacin)	29	4	5	7	2	2	0	1	0	8
Combined with tetracyclines(minocycline/moxicycline/tigecycline)	4	0	2	0	1	0	0	0	1	0
Triple therapy with two other classes of drug	155 (29.19%)	57 (42.22%)	20 (20.20%)	8 (10.53%)	24 (38.71%)	12 (22.22%)	4 (30.77%)	5 (31.25%)	1	24 (33.80%)
Combined with linezolid + carbapenems (imipenem/meropenem)	56 (36.13%)	24 (42.11%)	4	1	9	4	3	1	0	10 (41.67%)
Combined with linezolid + amikacin	6	2	2	0	1	1	0	0	0	0
Combined with linezolid + cephalosporins/penicillins β -lactamase inhibitors	8	4	0	0	3	0	0	1	0	0
Combined with linezolid + tetracyclines (minocycline/doxycycline/tigecycline)	2	1	0	0	1	0	0	0	0	0
Combined with linezolid + quinolones (moxifloxacin/levofloxacin)	6	2	2	1	0	0	0	0	0	1
Combined with amikacin + carbapenems (imipenem/meropenem)	26 (16.77%)	12 (21.05%)	4	1	6	3	0	0	0	0
Combined with amikacin + cephalosporins/penicillins β -lactamase inhibitors	7	2	1	2	0	1	1	0	0	0
Combined with amikacin + tetracyclines (minocycline/doxycycline/tigecycline)	4	2	0	0	0	0	0	0	0	2
Combined with amikacin + quinolones (moxifloxacin/levofloxacin)	1	0	0	0	1	0	0	0	0	0
Combined with tetracyclines + cephalosporins/carbapenems	7	2	0	0	1	0	0	2	1	1
Combined with fluoroquinolones + cephalosporins/carbapenems	19 (12.26%)	2	5	2	0	1	0	1	0	8
Combined with carbapenems (imipenem/meropenem) + cephalosporins	13	4	2	1	2	2	0	0	0	2
Other classes of drugs treatment besides sulfonamides	65 (10.91%)	22 (14.01%)	11 (10%)	6 (7.32%)	4 (6.06%)	8 (12.90%)	3 (18.75%)	3 (15.79%)	1 (16.67%)	7 (8.97%)
Quinolones (levofloxacin/moxifloxacin)	18 (27.69%)	10 (45.45%)	1	1	0	2	0	1	0	3
Monotherapy	7	5	1	1	0	0	0	0	0	0
Combined with penicillins/cephalosporins β -lactamase inhibitors	5	2	0	0	0	1	0	1	0	1
Combined with carbapenems + cephalosporins	3	2	0	0	0	0	0	0	0	1
Combined with linezolid + tetracyclines (minocycline)	0	0	0	0	0	0	0	0	0	0
Combined with tetracyclines (minocycline) + cephalosporins	2	0	0	0	0	1	0	0	0	1
Combined with clarithromycin	1	1	0	0	0	0	0	0	0	0
Amikacin	13 (20%)	5	0	1	0	3	3	0	0	1
Monotherapy	3	1	0	0	0	2	0	0	0	0
Combined with linezolid	2	2	0	0	0	0	0	0	0	0
Combined with clarithromycin	1	0	0	0	0	0	0	0	0	1
Combined with quinolones (levofloxacin/moxifloxacin)	4	2	0	1	0	1	0	0	0	0
Combined with carbapenems (imipenem/meropenem) + linezolid	3	0	0	0	0	0	3	0	0	0
Combined with carbapenems (imipenem) + penicillins/cephalosporins β -lactamase inhibitors	0	0	0	0	0	0	0	0	0	0
Linezolid	10	2	2	0	3	2	0	0	1	0
Monotherapy	4	0	1	0	1	1	0	0	1	0
Combined with carbapenems (imipenem/meropenem)	6	2	1	0	2	1	0	0	0	0
Combined with tetracyclines (minocycline/tigecycline)	0	0	0	0	0	0	0	0	0	0
Carbapenems (imipenem/meropenem)	5	1	1	1	0	1	0	0	0	1
Monotherapy	4	0	1	1	0	1	0	0	0	1
Combined with cephalosporins (cefoperazone-sulbactam)	1	1	0	0	0	0	0	0	0	0
Penicillins/cephalosporins β -lactamase inhibitors	16	4	5	3	1	0	0	1	0	2
Tetracyclines + penicillins/cephalosporins β -lactamase inhibitors	3	0	2	0	0	0	0	1	0	0